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Abstract
Children diagnosed with high grade gliomas (HGG) have dismal prognoses and treatment options remain
limited. Tumor treating fields (TTFields) in combination with temozolomide (TMZ) is approved for the
treatment of newly diagnosed and recurrent glioblastoma (GBM) in adult patients. However, clinical
experience with TTFields in the pediatric HGG population is lacking.
This retrospective review of four clinical cases was undertaken to evaluate the feasibility of treating children
diagnosed with HGG off-label with TTFields. Patients were evaluated for device compliance, safety, and
outcome. Treatment with TTFields was delivered via four transducer arrays placed on the shaved scalp,
which were connected to a portable device generating 200 kHz alternating electric fields.
One female and three male patients (ages 4-16 years) with heavily pretreated HGG were treated with
TTFields off-label from March 2015 to December 2016. In three of these cases, TTFields were administered in
combination with TMZ. Across all four patient cases, average wear compliance rates ranged between 53%
and 92%. No device-related toxicities were reported during treatment with TTFields delivered for up to four
months. All patients eventually died of the disease.
TTFields was well tolerated in our limited cohort of patients. Compliance times were similar to what has
been reported in adults without significant toxicity. Further studies of the efficacy and safety of TTFields in
children with HGG are underway in a clinical trial setting.
Categories: Neurology, Oncology
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Introduction
Glioblastoma (GBM) is a highly malignant brain tumor typically diagnosed in older adults (median age 64
years) and is very rare in children [1-2]. In the US population, over the period 2009-2013, only 1.25% of all
cases of GBM occurred in those aged under 20 years; GBM represented only 2.9% of central nervous system
tumors reported in children up to 19 years of age [3]. Similar to adult patients with GBM, the prognosis in
children with GBM is generally very poor. Median survival time for adults with GBM has been reported as
only 14.6 months [4], although there is some evidence that younger patients survive slightly longer, perhaps
related to better performance status [5]. Recent US data showed a two-year survival of 33.3% and a five-year
survival of 16.8% in patients with GBM below 20 years of age compared with 16.9% and 5.5%, respectively,
across all age groups [3].
Prior to tumor treating fields (TTFields), treatment recommendations for adult patients with GBM (up to 70
years of age) involved a multidisciplinary approach of maximum safe surgical resection, radiotherapy, and
concurrent and adjuvant chemotherapy [6]. The addition of the oral alkylating agent temozolomide (TMZ) to
radiation treatment has been shown to prolong survival by 15-17 months in adult patients with GBM (two-
year overall survival [OS] rate of 26% in adults with GBM vs 10% for radiation therapy alone) [4,6-7]. In
pediatric high grade gliomas (HGG), TMZ has failed to show improved outcomes in the clinical trial setting
[8].
TTFields are non-invasive, low-intensity, intermediate frequency (200 kHz), alternating electric fields,
delivered in a loco-regional manner. The inhibitory effect of TTFields on cell growth is mainly mediated by
interference with the mitotic cell cycle, in particular during metaphase, anaphase, and telophase [9-10].
Treatment with TTFields in combination with TMZ maintenance therapy has been shown to significantly
prolong survival and is well tolerated in adults with newly diagnosed GBM [11]. TTFields has also been
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shown to be as effective as chemotherapy in adults with recurrent GBM and is associated with improved
quality of life [12]. Based on these trial results, TTFields therapy was approved for adults with recurrent and
newly diagnosed GBM, but is currently not approved for use in pediatric patients. Until more recently, there
was no reported experience of TTFields in pediatric GBM. A single case study reported the benefits of
TTFields therapy combined with bevacizumab in one pediatric patient with GBM in whom TTFields
treatment was associated with stable disease for seven months with minimal adverse events [13]. A case
series of TTFields in five pediatric patients (ages 10-20 years) with high-grade gliomas showed that the
treatment was well tolerated without treatment-limiting toxicities [14]. Here we review our retrospective
series of four patients diagnosed with HGG treated with TTFields off-label, including the two youngest




A 15-year-old girl with a history of high-risk, pre-B cell acute lymphoblastic leukemia that was treated with
multimodality chemotherapy and whole-brain photon irradiation (1800 cGy) presented two years after
completion of therapy with behavioral changes. Magnetic resonance imaging (MRI) revealed a large left
frontal-temporal neoplasm. The patient underwent gross total resection and the pathology was consistent
with a diagnosis of GBM. Her treatment included oral daily TMZ and focal intensity-modulated radiation
(photon) therapy. After completion of radiation therapy, maintenance treatment was started with
maintenance TMZ and TTFields. Treatment with TTFields was well tolerated and was not associated with
device-related side effects. Over the course of TTFields treatment, the average wear compliance rate for the
patient was between 47.4% and 67.8% (Figure 1A). Two months after initiation of TTFields therapy, MRI
showed disease progression and she died from her disease two months later.
Case 2
A 9-year-old boy presented with a several-month history of vomiting and headache, previously diagnosed as
sinusitis. An MRI scan revealed a large posterior parietal neoplasm spanning the corpus callosum, without
evidence of leptomeningeal metastatic disease.
Subtotal surgical resection was undertaken and the pathology was consistent with GBM. The patient
subsequently underwent photon radiation with concomitant daily TMZ until progression four months after
initial diagnosis. At this time, he was treated with TTFields in combination with TMZ, everolimus, and
bevacizumab. No device-related toxicities were evident during the duration of TTFields therapy. An average
wear compliance rates ranged from 52.2%-68.9% (Figure 1B). Three months after initiation of TTFields
therapy, MRI showed progression and the patient subsequently died two months later.
Case 3
A 4-year-old boy presented with a three-week history of fatigue and progressive encephalopathy. An MRI
scan revealed a large contrast-enhancing tumor localized to the left frontal temporal lobe. Following
subtotal resection of the tumor that revealed a GBM, the patient failed treatments with carboplatin,
vincristine, and TMZ and later focal photon radiation therapy, bevacizumab, temozolomide, irinotecan, and
vorinostat. The patient began treatment with TTFields 14 months after initial diagnosis, which was
continued for two months without evidence of device-related toxicity. The average wear compliance rate
ranged from 91.2% to 92.1% (Figure 1C). The patient died of disease three months after initiation of
TTFields.
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FIGURE 1: Tumor treating fields (TTFields) Compliance of Pediatric
Patients
Compliance rates are illustrated for patients 1-3 with a target of 75%.
Case 4
A 16-year-old male patient with a known germline p53 mutation, identified by TP53 gene-sequencing
analysis after his mother died of leiomyosarcoma and his brother was treated for rhabdomyosarcoma,
presented with a new onset seizure. MRI showed multifocal white matter signal abnormalities in the right
occipital/parietal/temporal lobes with extension on T2/fluid attenuated inversion recovery (FLAIR)
hyperintensity through the splenium of the corpus callosum. Biopsy revealed an anaplastic astrocytoma
histology with a pattern of gliomatosis cerebri on neuroimaging.
His treatment prior therapies included radiation therapy, TMZ, bevacizumab, and a programmed death
receptor ligand 1 (PDL-1) inhibitor as part of a clinical trial. Thirteen months after diagnosis, he was treated
with TTFields in combination with daily TMZ. Therapy was well tolerated with no side-effects; specifically,
no worsening of headache or skin irritation were reported. Unfortunately, no information on wear
compliance was available for this patient. TTFields therapy was discontinued three months after initiation of
therapy secondary to progression and the patient died of disease six months later.
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Discussion
The efficacy and safety of TTFields have not been extensively investigated in the pediatric brain tumor
population and few data are available almost five years since the seminal adult clinical trial demonstrating
its efficacy in adults with GBM multiforme [11]. Our case series adds to the previously reported five pediatric
patients treated with TTFields [13-14] regarding the safety and tolerability. Our series describes two of the
youngest patients ever to be reported with TTFields treatment.
Over the treatment periods of up to four months, adjuvant therapy with TTFields was well tolerated in these
heavily pre-treated pediatric cases, and there were no device-related toxicities. These results are consistent
with other recently reported cases [12-13]. Although limited conclusions can be drawn from this experience
in children with heavily treated HGG, these preliminary safety observations in pediatric patients are
consistent with the safety profile of adjuvant TTFields in adult GBM populations [11-12]. Local skin
reactions have been reported with TTFields as a result of long-term wear [15-16]. None of our patients had
any significant skin reactions.
As reported in a post-hoc analysis of the EF-11 trial of TTFields versus best clinical practice in adults with
recurrent GBM, significantly higher survival was reported in patients with a wear compliance rate of ≥75%
versus <75% (median OS 7.7 vs 4.5 months; P=0.042 [17]. Moreover, survival duration increased with
increasing compliance [17]. Among the four pediatric cases presented here, the three-week average wear
compliance ranged from 53% to 92% (median 68%) during the treatment periods, with night use of TTFields
generally higher than day use. The compliance rate among this small group of pediatric patients is
encouraging given positive associations between OS and higher wear compliance. It is unknown if outcomes
would have been affected by improved compliance.
Our findings should be viewed with significant limitations aside from the retrospective nature and small
number of patients. Our patients were very heavily pretreated and the use of TTFields was utilized many
months after completion of standard radiation therapy. Furthermore, the compliance data was only
available for three of four patients. All patients were treated off-label and outside of a clinical trial setting;
no meaningful conclusions regarding efficacy can be determined. A clinical trial testing the feasibility of
TTFields in children with recurrent or progressive supratentorial HGG and ependymoma is ongoing
(NCT03598244).
Conclusions
Our preliminary findings suggest that children with HGGs can tolerate TTFields for long durations per day
and for treatment periods of up to four months without device-related toxicity. Feasibility studies of
TTFields in pediatric patients with HGG in the clinical trial setting are ongoing.
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